PAR:ABNX

ABIONYX Pharma S.A. · PAR · Healthcare · EUR · FY for 2025

Figures on this page computed 2026-11-08 13:23 UTC

Last close

n/aEUR

Market data

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-08
Reported in
EUR
- computed
- Computed from the filing for 2025
-122.4%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-08
Reported in
EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
-136.6%Net margin
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
-78.1%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
0.89Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-08
Reported in
EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-08
Reported in
EUR
- computed

Price is the furthest below its sector's middle: 0.08 against 0.38 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Ten years as a story

lens 9 of 9

We hold no filed year for this company, so there is nothing to read.

Nothing is drawn in its place. The other lenses are unaffected.